Genetic variation and function of the HIV-1 Tat protein

Rana TM, Jeang KT (1999) Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA. Arch Biochem Biophys 365(2):175–185. https://doi.org/10.1006/abbi.1999.1206 Li L, Dahiya S, Kortagere S, Aiamkitsumrit B, Cunningham D, Pirrone V, Nonnemacher MR, Wigdahl B (2012) Impact of Tat genetic variation on HIV-1 disease. Adv Virol 2012:123605. https://doi.org/10.1155/2012/123605 Gu J, Babayeva ND, Suwa Y, Baranovskiy AG, Price DH, Tahirov TH (2014) Crystal structure of HIV-1 Tat complexed with human P-TEFb and AFF4. Cell Cycle 13(11):1788–1797. https://doi.org/10.4161/cc.28756 Price DH (2000) P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol 20(8):2629–2634 Jeang KT, Xiao H, Rich EA (1999) Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem 274(41):28837–28840 Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, Josephs SF, Doran ER, Rafalski JA, Whitehorn EA, Baumeister K et al (1985) Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313(6000):277–284 Rayne F, Debaisieux S, Yezid H, Lin YL, Mettling C, Konate K, Chazal N, Arold ST, Pugniere M, Sanchez F, Bonhoure A, Briant L, Loret E, Roy C, Beaumelle B (2010) Phosphatidylinositol-(4,5)-bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cells. EMBO J 29(8):1348–1362. https://doi.org/10.1038/emboj.2010.32 Koken SE, Greijer AE, Verhoef K, van Wamel J, Bukrinskaya AG, Berkhout B (1994) Intracellular analysis of in vitro modified HIV Tat protein. J Biol Chem 269(11):8366–8375 Pierleoni R, Menotta M, Antonelli A, Sfara C, Serafini G, Dominici S, Laguardia ME, Salis A, Damonte G, Banci L, Porcu M, Monini P, Ensoli B, Magnani M (2010) Effect of the redox state on HIV-1 tat protein multimerization and cell internalization and trafficking. Mol Cell Biochem 345(1–2):105–118. https://doi.org/10.1007/s11010-010-0564-9 Ranga U, Shankarappa R, Siddappa NB, Ramakrishna L, Nagendran R, Mahalingam M, Mahadevan A, Jayasuryan N, Satishchandra P, Shankar SK, Prasad VR (2004) Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. J Virol 78(5):2586–2590 Wei P, Garber ME, Fang SM, Fischer WH, Jones KA (1998) A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92(4):451–462 Marzio G, Tyagi M, Gutierrez MI, Giacca M (1998) HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc Natl Acad Sci USA 95(23):13519–13524 Jeang KT, Chun R, Lin NH, Gatignol A, Glabe CG, Fan H (1993) In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor. J Virol 67(10):6224–6233 Hauber J, Malim MH, Cullen BR (1989) Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein. J Virol 63(3):1181–1187 Mukerjee R, Sawaya BE, Khalili K, Amini S (2007) Association of p65 and C/EBPbeta with HIV-1 LTR modulates transcription of the viral promoter. J Cell Biochem 100(5):1210–1216. https://doi.org/10.1002/jcb.21109 Ruben S, Perkins A, Purcell R, Joung K, Sia R, Burghoff R, Haseltine WA, Rosen CA (1989) Structural and functional characterization of human immunodeficiency virus tat protein. J Virol 63(1):1–8 van der Kuyl AC, Vink M, Zorgdrager F, Bakker M, Wymant C, Hall M, Gall A, Blanquart F, Berkhout B, Fraser C, Cornelissen M, Collaboration B (2018) The evolution of subtype B HIV-1 tat in the Netherlands during 1985–2012. Virus Res 250:51–64. https://doi.org/10.1016/j.virusres.2018.04.008 Neuveut C, Scoggins RM, Camerini D, Markham RB, Jeang KT (2003) Requirement for the second coding exon of Tat in the optimal replication of macrophage-tropic HIV-1. J Biomed Sci 10(6 Pt 1):651–660. https://doi.org/10.1159/000073531 Kukkonen S, Martinez-Viedma Mdel P, Kim N, Manrique M, Aldovini A (2014) HIV-1 Tat second exon limits the extent of Tat-mediated modulation of interferon-stimulated genes in antigen presenting cells. Retrovirology 11:30. https://doi.org/10.1186/1742-4690-11-30 Lopez-Huertas MR, Mateos E, Sanchez Del Cojo M, Gomez-Esquer F, Diaz-Gil G, Rodriguez-Mora S, Lopez JA, Calvo E, Lopez-Campos G, Alcami J, Coiras M (2013) The presence of HIV-1 Tat protein second exon delays fas protein-mediated apoptosis in CD4 + T lymphocytes: a potential mechanism for persistent viral production. J Biol Chem 288(11):7626–7644. https://doi.org/10.1074/jbc.M112.408294 Aiamkitsumrit B, Dampier W, Martin-Garcia J, Nonnemacher MR, Pirrone V, Ivanova T, Zhong W, Kilareski E, Aldigun H, Frantz B, Rimbey M, Wojno A, Passic S, Williams JW, Shah S, Blakey B, Parikh N, Jacobson JM, Moldover B, Wigdahl B (2014) Defining differential genetic signatures in CXCR4- and the CCR5-utilizing HIV-1 co-linear sequences. PLoS One 9(9):e107389. https://doi.org/10.1371/journal.pone.0107389 Chiodelli P, Urbinati C, Mitola S, Tanghetti E, Rusnati M (2012) Sialic acid associated with alphavbeta3 integrin mediates HIV-1 Tat protein interaction and endothelial cell proangiogenic activation. J Biol Chem 287(24):20456–20466. https://doi.org/10.1074/jbc.M111.337139 Urbinati C, Mitola S, Tanghetti E, Kumar C, Waltenberger J, Ribatti D, Presta M, Rusnati M (2005) Integrin alphavbeta3 as a target for blocking HIV-1 Tat-induced endothelial cell activation in vitro and angiogenesis in vivo. Arterioscler Thromb Vasc Biol 25(11):2315–2320. https://doi.org/10.1161/01.ATV.0000186182.14908.7b Lopez-Huertas MR, Callejas S, Abia D, Mateos E, Dopazo A, Alcami J, Coiras M (2010) Modifications in host cell cytoskeleton structure and function mediated by intracellular HIV-1 Tat protein are greatly dependent on the second coding exon. Nucleic Acids Res 38(10):3287–3307. https://doi.org/10.1093/nar/gkq037 Canducci F, Marinozzi MC, Sampaolo M, Berre S, Bagnarelli P, Degano M, Gallotta G, Mazzi B, Lemey P, Burioni R, Clementi M (2009) Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects. Retrovirology 6:4. https://doi.org/10.1186/1742-4690-6-4 Rhee SY, Fessel WJ, Zolopa AR, Hurley L, Liu T, Taylor J, Nguyen DP, Slome S, Klein D, Horberg M, Flamm J, Follansbee S, Schapiro JM, Shafer RW (2005) HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis 192(3):456–465. https://doi.org/10.1086/431601 Dampier W, Nonnemacher MR, Mell J, Earl J, Ehrlich GD, Pirrone V, Aiamkitsumrit B, Zhong W, Kercher K, Passic S, Williams JW, Jacobson JM, Wigdahl B (2016) HIV-1 genetic variation resulting in the development of new quasispecies continues to be encountered in the peripheral blood of well-suppressed patients. PLoS One 11(5):e0155382. https://doi.org/10.1371/journal.pone.0155382 Roy CN, Khandaker I, Oshitani H (2015) Intersubtype genetic variation of HIV-1 Tat Exon 1. AIDS Res Hum Retroviruses 31(6):641–648. https://doi.org/10.1089/AID.2014.0346 Roy CN, Khandaker I, Oshitani H (2015) Evolutionary dynamics of Tat in HIV-1 subtypes B and C. PLoS One 10(6):e0129896. https://doi.org/10.1371/journal.pone.0129896 Li L, Aiamkitsumrit B, Pirrone V, Nonnemacher MR, Wojno A, Passic S, Flaig K, Kilareski E, Blakey B, Ku J, Parikh N, Shah R, Martin-Garcia J, Moldover B, Servance L, Downie D, Lewis S, Jacobson JM, Kolson D, Wigdahl B (2011) Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol 17(1):92–109. https://doi.org/10.1007/s13365-010-0014-1 Liu Y, Li J, Kim BO, Pace BS, He JJ (2002) HIV-1 Tat protein-mediated transactivation of the HIV-1 long terminal repeat promoter is potentiated by a novel nuclear Tat-interacting protein of 110 kDa, Tip110. J Biol Chem 277(26):23854–23863. https://doi.org/10.1074/jbc.M200773200 Rossenkhan R, MacLeod IJ, Sebunya TK, Castro-Nallar E, McLane MF, Musonda R, Gashe BA, Novitsky V, Essex M (2013) tat Exon 1 exhibits functional diversity during HIV-1 subtype C primary infection. J Virol 87(10):5732–5745. https://doi.org/10.1128/JVI.03297-12 Campbell GR, Loret EP, Spector SA (2010) HIV-1 clade B Tat, but not clade C Tat, increases X4 HIV-1 entry into resting but not activated CD4 + T cells. J Biol Chem 285(3):1681–1691. https://doi.org/10.1074/jbc.M109.049957 Mishra M, Vetrivel S, Siddappa NB, Ranga U, Seth P (2008) Clade-specific differences in neurotoxicity of human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 motif. Ann Neurol 63(3):366–376. https://doi.org/10.1002/ana.21292 Tyor W, Fritz-French C, Nath A (2013) Effect of HIV clade differences on the onset and severity of HIV-associated neurocognitive disorders. J Neurovirol 19(6):515–522. https://doi.org/10.1007/s13365-013-0206-6 Shah S, Alexaki A, Pirrone V, Dahiya S, Nonnemacher MR, Wigdahl B (2014) Functional properties of the HIV-1 long terminal repeat containing single-nucleotide polymorphisms in Sp site III and CCAAT/enhancer binding protein site I. Virol J 11:92. https://doi.org/10.1186/1743-422X-11-92 Kilareski EM, Shah S, Nonnemacher MR, Wigdahl B (2009) Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage. Retrovirology 6:118. https://doi.org/10.1186/1742-4690-6-118 Burdo TH, Nonnemacher M, Irish BP, Choi CH, Krebs FC, Gartner S, Wigdahl B (2004) High-affinity interaction between HIV-1 Vpr and specific sequences that span the C/EBP and adjacent NF-kappaB sites within the HIV-1 LTR correlate with HIV-1-associated dementia. DNA Cell Biol 23(4):261–269. https://doi.org/10.1089/104454904773819842 Maubert ME, Pirrone V, Rivera NT, Wigdahl B, Nonnemacher MR (2015) Interaction between Tat and drugs of abuse during HIV-1 infection and central nervous system disease. Front Microbiol 6:1512. https://doi.org/10.3389/fmicb.2015.01512 Clifford DB (2017) HIV-associated neurocognitive disorder. Curr Opin Infect Dis 30(1):117–122. https://doi.org/10.1097/QCO.0000000000000328 Kaul M, Garden GA, Lipton SA (2001) Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410(6831):988–994. https://doi.org/10.1038/35073667 Dahiya S, Irish BP, Nonnemacher MR, Wigdahl B (2013) Genetic variation and HIV-associated neurologic disease. Adv Virus Res 87:183–240. https://doi.org/10.1016/B978-0-12-407698-3.00006-5 Andras IE, Pu H, Deli MA, Nath A, Hennig B, Toborek M (2003) HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. J Neurosci Res 74(2):255–265. https://doi.org/10.1002/jnr.10762 Albini A, Ferrini S, Benelli R, Sforzini S, Giunciuglio D, Aluigi MG, Proudfoot AE, Alouani S, Wells TN, Mariani G, Rabin RL, Farber JM, Noonan DM (1998) HIV-1 Tat protein mimicry of chemokines. Proc Natl Acad Sci USA 95(22):13153–13158 Pu H, Tian J, Flora G, Lee YW, Nath A, Hennig B, Toborek M (2003) HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Mol Cell Neurosci 24(1):224–237 Agrawal L, Louboutin JP, Reyes BA, Van Bockstaele EJ, Strayer DS (2012) HIV-1 Tat neurotoxicity: a model of acute and chronic exposure, and neuroprotection by gene delivery of antioxidant enzymes. Neurobiol Dis 45(2):657–670. https://doi.org/10.1016/j.nbd.2011.10.005 Badou A, Bennasser Y, Moreau M, Leclerc C, Benkirane M, Bahraoui E (2000) Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway. J Virol 74(22):10551–10562 Brady J, Kashanchi F (2005) Tat gets the “green” light on transcription initiation. Retrovirology 2:69. https://doi.org/10.1186/1742-4690-2-69 Cullen BR (1991) Regulation of HIV-1 gene expression. FASEB J 5(10):2361–2368 Feinberg MB, Baltimore D, Frankel AD (1991) The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc Natl Acad Sci USA 88(9):4045–4049 Purcell DF, Martin MA (1993) Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol 67(11):6365–6378 Truant R, Cullen BR (1999) The arginine-rich domains present in human immunodeficiency virus type 1 Tat and Rev function as direct importin beta-dependent nuclear localization signals. Mol Cell Biol 19(2):1210–1217 Efthymiadis A, Briggs LJ, Jans DA (1998) The HIV-1 Tat nuclear localization sequence confers novel nuclear import properties. J Biol Chem 273(3):1623–1628 Cardarelli F, Serresi M, Bizzarri R, Beltram F (2008) Tuning the transport properties of HIV-1 Tat arginine-rich motif in living cells. Traffic 9(4):528–539. https://doi.org/10.1111/j.1600-0854.2007.00696.x Smith KM, Himiari Z, Tsimbalyuk S, Forwood JK (2017) Structural Basis for Importin-alpha Binding of the Human Immunodeficiency Virus Tat. Sci Rep 7(1):1650. https://doi.org/10.1038/s41598-017-01853-7 Bres V, Kiernan R, Emiliani S, Benkirane M (2002) Tat acetyl-acceptor lysines are important for human immunodeficiency virus type-1 replication. J Biol Chem 277(25):22215–22221. https://doi.org/10.1074/jbc.M201895200 Fulcher AJ, Sivakumaran H, Jin H, Rawle DJ, Harrich D, Jans DA (2016) The protein arginine methyltransferase PRMT6 inhibits HIV-1 Tat nucleolar retention. Biochim Biophys Acta 1863(2):254–262. https://doi.org/10.1016/j.bbamcr.2015.11.019 Kuppuswamy M, Subramanian T, Srinivasan A, Chinnadurai G (1989) Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis. Nucleic Acids Res 17(9):3551–3561 Orsini MJ, Debouck CM (1996) Inhibition of human immunodeficiency virus type 1 and type 2 Tat function by transdominant Tat protein localized to both the nucleus and cytoplasm. J Virol 70(11):8055–8063 He M, Zhang L, Wang X, Huo L, Sun L, Feng C, Jing X, Du D, Liang H, Liu M, Hong Z, Zhou J (2013) Systematic analysis of the functions of lysine acetylation in the regulation of Tat activity. PLoS One 8(6):e67186. https://doi.org/10.1371/journal.pone.0067186 Ott M, Schnolzer M, Garnica J, Fischle W, Emiliani S, Rackwitz HR, Verdin E (1999) Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity. Curr Biol 9(24):1489–1492 D’Orso I, Frankel AD (2009) Tat acetylation modulates assembly of a viral-host RNA-protein transcription complex. Proc Natl Acad Sci USA 106(9):3101–3106. https://doi.org/10.1073/pnas.0900012106 Grisendi S, Mecucci C, Falini B, Pandolfi PP (2006) Nucleophosmin and cancer. Nat Rev Cancer 6(7):493–505. https://doi.org/10.1038/nrc1885 Li YP (1997) Protein B23 is an important human factor for the nucleolar localization of the human immunodeficiency virus protein Tat. J Virol 71(5):4098–4102 Marasco WA, Szilvay AM, Kalland KH, Helland DG, Reyes HM, Walter RJ (1994) Spatial association of HIV-1 tat protein and the nucleolar transport protein B23 in stably transfected Jurkat T-cells. Arch Virol 139(1–2):133–154 Gadad SS, Rajan RE, Senapati P, Chatterjee S, Shandilya J, Dash PK, Ranga U, Kundu TK (2011) HIV-1 infection induces acetylation of NPM1 that facilitates Tat localization and enhances viral transactivation. J Mol Biol 410(5):997–1007. https://doi.org/10.1016/j.jmb.2011.04.009 Boulanger MC, Liang C, Russell RS, Lin R, Bedford MT, Wainberg MA, Richard S (2005) Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression. J Virol 79(1):124–131. https://doi.org/10.1128/JVI.79.1.124-131.2005 Xie B, Invernizzi CF, Richard S, Wainberg MA (2007) Arginine methylation of the human immunodeficiency virus type 1 Tat protein by PRMT6 negatively affects Tat interactions with both cyclin T1 and the Tat transactivation region. J Virol 81(8):4226–4234. https://doi.org/10.1128/JVI.01888-06 Frankel A, Yadav N, Lee J, Branscombe TL, Clarke S, Bedford MT (2002) The novel human protein arginine N-methyltransferase PRMT6 is a nuclear enzyme displaying unique substrate specificity. J Biol Chem 277(5):3537–3543. https://doi.org/10.1074/jbc.M108786200 Yoon CH, Kim SY, Byeon SE, Jeong Y, Lee J, Kim KP, Park J, Bae YS (2015) p53-derived host restriction of HIV-1 replication by protein kinase R-mediated Tat phosphorylation and inactivation. J Virol 89(8):4262–4280. https://doi.org/10.1128/JVI.03087-14 Hernandez-Verdun D, Roussel P, Thiry M, Sirri V, Lafontaine DL (2010) The nucleolus: structure/function relationship in RNA metabolism. Wiley Interdiscip Rev RNA 1(3):415–431. https://doi.org/10.1002/wrna.39 Ponti D, Troiano M, Bellenchi GC, Battaglia PA, Gigliani F (2008) The HIV Tat protein affects processing of ribosomal RNA precursor. BMC Cell Biol 9:32. https://doi.org/10.1186/1471-2121-9-32 Jarboui MA, Bidoia C, Woods E, Roe B, Wynne K, Elia G, Hall WW, Gautier VW (2012) Nucleolar protein trafficking in response to HIV-1 Tat: rewiring the nucleolus. PLoS One 7(11):e48702. https://doi.org/10.1371/journal.pone.0048702 Sonenberg N, Hinnebusch AG (2009) Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136(4):731–745. https://doi.org/10.1016/j.cell.2009.01.042 Schneider RJ, Shenk T (1987) Impact of virus infection on host cell protein synthesis. Annu Rev Biochem 56:317–332. https://doi.org/10.1146/annurev.bi.56.070187.001533 Bushell M, Sarnow P (2002) Hijacking the translation apparatus by RNA viruses. J Cell Biol 158(3):395–399. https://doi.org/10.1083/jcb.200205044 Debaisieux S, Rayne F, Yezid H, Beaumelle B (2012) The ins and outs of HIV-1 Tat. Traffic 13(3):355–363. https://doi.org/10.1111/j.1600-0854.2011.01286.x Vendeville A, Rayne F, Bonhoure A, Bettache N, Montcourrier P, Beaumelle B (2004) HIV-1 Tat enters T cells using coated pits before translocating from acidified endosomes and eliciting biological responses. Mol Biol Cell 15(5):2347–2360. https://doi.org/10.1091/mbc.E03-12-0921 Yezid H, Konate K, Debaisieux S, Bonhoure A, Beaumelle B (2009) Mechanism for HIV-1 Tat insertion into the endosome membrane. J Biol Chem 284(34):22736–22746. https://doi.org/10.1074/jbc.M109.023705 Pantano S, Tyagi M, Giacca M, Carloni P (2002) Amino acid modification in the HIV-1 Tat basic domain: insights from molecular dynamics and in vivo functional studies. J Mol Biol 318(5):1331–1339 Tyagi M, Rusnati M, Presta M, Giacca M (2001) Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 276(5):3254–3261. https://doi.org/10.1074/jbc.M006701200 Mere J, Morlon-Guyot J, Bonhoure A, Chiche L, Beaumelle B (2005) Acid-triggered membrane insertion of Pseudomonas exotoxin A involves an original mechanism based on pH-regulated tryptophan exposure. J Biol Chem 280(22):21194–21201. https://doi.org/10.1074/jbc.M412656200 De Matteis MA, Godi A (2004) PI-loting membrane traffic. Nat Cell Biol 6(6):487–492. https://doi.org/10.1038/ncb0604-487 Di Paolo G, De Camilli P (2006) Phosphoinositides in cell regulation and membrane dynamics. Nature 443(7112):651–657. https://doi.org/10.1038/nature05185 Boven LA, Noorbakhsh F, Bouma G, van der Zee R, Vargas DL, Pardo C, McArthur JC, Nottet HS, Power C (2007) Brain-derived human immunodeficiency virus-1 Tat exerts differential effects on LTR transactivation and neuroimmune activation. J Neurovirol 13(2):173–184. https://doi.org/10.1080/13550280701258399 Cowley D, Gray LR, Wesselingh SL, Gorry PR, Churchill MJ (2011) Genetic and functional heterogeneity of CNS-derived tat alleles from patients with HIV-associated dementia. J Neurovirol 17(1):70–81. https://doi.org/10.1007/s13365-010-0002-5 Roof P, Ricci M, Genin P, Montano MA, Essex M, Wainberg MA, Gatignol A, Hiscott J (2002) Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator. Virology 296(1):77–83. https://doi.org/10.1006/viro.2001.1397 Dahiya S, Nonnemacher MR, Wigdahl B (2012) Deployment of the human immunodeficiency virus type 1 protein arsenal: combating the host to enhance viral transcription and providing targets for therapeutic development. J Gen Virol 93(Pt 6):1151–1172. https://doi.org/10.1099/vir.0.041186-0 Taylor JP, Pomerantz R, Bagasra O, Chowdhury M, Rappaport J, Khalili K, Amini S (1992) TAR-independent transactivation by Tat in cells derived from the CNS: a novel mechanism of HIV-1 gene regulation. EMBO J 11(9):3395–3403 Hetzer C, Dormeyer W, Schnolzer M, Ott M (2005) Decoding Tat: the biology of HIV Tat posttranslational modifications. Microbes Infect 7(13):1364–1369. https://doi.org/10.1016/j.micinf.2005.06.003 Deng L, Ammosova T, Pumfery A, Kashanchi F, Nekhai S (2002) HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter. J Biol Chem 277(37):33922–33929. https://doi.org/10.1074/jbc.M111349200 Ammosova T, Berro R, Jerebtsova M, Jackson A, Charles S, Klase Z, Southerland W, Gordeuk VR, Kashanchi F, Nekhai S (2006) Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription. Retrovirology 3:78. https://doi.org/10.1186/1742-4690-3-78 Ivanov A, Lin X, Ammosova T, Ilatovskiy AV, Kumari N, Lassiter H, Afangbedji N, Niu X, Petukhov MG, Nekhai S (2018) HIV-1 Tat phosphorylation on Ser-16 residue modulates HIV-1 transcription. Retrovirology 15(1):39. https://doi.org/10.1186/s12977-018-0422-5 Stevenson-Lindert LM, Fowler P, Lew J (2003) Substrate specificity of CDK2-cyclin A. What is optimal? J Biol Chem 278(51):50956–50960. https://doi.org/10.1074/jbc.M306546200 Kitagawa M, Higashi H, Jung HK, Suzuki-Takahashi I, Ikeda M, Tamai K, Kato J, Segawa K, Yoshida E, Nishimura S, Taya Y (1996) The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J 15(24):7060–7069 Selhorst P, Combrinck C, Ndabambi N, Ismail SD, Abrahams MR, Lacerda M, Samsunder N, Garrett N, Abdool Karim Q, Abdool Karim SS, Williamson C (2017) Replication capacity of viruses from acute infection drives HIV-1 disease progression. J Virol. https://doi.org/10.1128/JVI.01806-16 Tyagi S, Ochem A, Tyagi M (2011) DNA-dependent protein kinase interacts functionally with the RNA polymerase II complex recruited at the human immunodeficiency virus (HIV) long terminal repeat and plays an important role in HIV gene expression. J Gen Virol 92(Pt 7):1710–1720. https://doi.org/10.1099/vir.0.029587-0 McMillan NA, Chun RF, Siderovski DP, Galabru J, Toone WM, Samuel CE, Mak TW, Hovanessian AG, Jeang KT, Williams BR (1995) HIV-1 Tat directly interacts with the interferon-induced, double-stranded RNA-dependent kinase. PKR Virol 213(2):413–424. https://doi.org/10.1006/viro.1995.0014 Brand SR, Kobayashi R, Mathews MB (1997) The Tat protein of human immunodeficiency virus type 1 is a substrate and inhibitor of the interferon-induced, virally activated protein kinase, PKR. J Biol Chem 272(13):8388–8395 Garcia MA, Gil J, Ventoso I, Guerra S, Domingo E, Rivas C, Esteban M (2006) Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev 70(4):1032–1060. https://doi.org/10.1128/MMBR.00027-06 Krishna KH, Vadlamudi Y, Kumar MS (2016) Viral evolved inhibition mechanism of the RNA Dependent protein kinase PKR’s kinase domain, a structural perspective. PLoS One 11(4):e0153680. https://doi.org/10.1371/journal.pone.0153680 Campbell GR, Loret EP (2009) What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS Vaccine?. Retrovirology 6:50. https://doi.org/10.1186/1742-4690-6-50 Endo-Munoz L, Warby T, Harrich D, McMillan NA (2005) Phosphorylation of HIV Tat by PKR increases interaction with TAR RNA and enhances transcription. Virol J 2:17. https://doi.org/10.1186/1743-422X-2-17 Deng L, de la Fuente C, Fu P, Wang L, Donnelly R, Wade JD, Lambert P, Li H, Lee CG, Kashanchi F (2000) Acetylation of HIV-1 Tat by CBP/P300 increases transcription of integrated HIV-1 genome and enhances binding to core histones. Virology 277(2):278–295. https://doi.org/10.1006/viro.2000.0593 Kiernan RE, Vanhulle C, Schiltz L, Adam E, Xiao H, Maudoux F, Calomme C, Burny A, Nakatani Y, Jeang KT, Benkirane M, Van Lint C (1999) HIV-1 tat transcriptional activity is regulated by acetylation. EMBO J 18(21):6106–6118. https://doi.org/10.1093/emboj/18.21.6106 Dorr A, Kiermer V, Pedal A, Rackwitz HR, Henklein P, Schubert U, Zhou MM, Verdin E, Ott M (2002) Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain. EMBO J 21(11):2715–2723. https://doi.org/10.1093/emboj/21.11.2715 Bres V, Tagami H, Peloponese JM, Loret E, Jeang KT, Nakatani Y, Emiliani S, Benkirane M, Kiernan RE (2002) Differential acetylation of Tat coordinates its interaction with the co-activators cyclin T1 and PCAF. EMBO J 21(24):6811–6819 Col E, Caron C, Seigneurin-Berny D, Gracia J, Favier A, Khochbin S (2001) The histone acetyltransferase, hGCN5, interacts with and acetylates the HIV transactivator, Tat. J Biol Chem 276(30):28179–28184. https://doi.org/10.1074/jbc.M101385200 Kaehlcke K, Dorr A, Hetzer-Egger C, Kiermer V, Henklein P, Schnoelzer M, Loret E, Cole PA, Verdin E, Ott M (2003) Acetylation of Tat defines a cyclinT1-independent step in HIV transactivation. Mol Cell 12(1):167–176 Mujtaba S, He Y, Zeng L, Farooq A, Carlson JE, Ott M, Verdin E, Zhou MM (2002) Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain. Mol Cell 9(3):575–586 Agbottah E, Deng L, Dannenberg LO, Pumfery A, Kashanchi F (2006) Effect of SWI/SNF chromatin remodeling complex on HIV-1 Tat activated transcription. Retrovirology 3:48. https://doi.org/10.1186/1742-4690-3-48 Tang L, Nogales E, Ciferri C (2010) Structure and function of SWI/SNF chromatin remodeling complexes and mechanistic implications for transcription. Prog Biophys Mol Biol 102(2–3):122–128. https://doi.org/10.1016/j.pbiomolbio.2010.05.001 Verdin E, Paras P, Van Lint C (1993) Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 12(8):3249–3259 Pagans S, Kauder SE, Kaehlcke K, Sakane N, Schroeder S, Dormeyer W, Trievel RC, Verdin E, Schnolzer M, Ott M (2010) The Cellular lysine methyltransferase Set7/9-KMT7 binds HIV-1 TAR RNA, monomethylates the viral transactivator Tat, and enhances HIV transcription. Cell Host Microbe 7(3):234–244. https://doi.org/10.1016/j.chom.2010.02.005 Ali I, Ramage H, Boehm D, Dirk LM, Sakane N, Hanada K, Pagans S, Kaehlcke K, Aull K, Weinberger L, Trievel R, Schnoelzer M, Kamada M, Houtz R, Ott M (2016) The HIV-1 Tat protein is monomethylated at lysine 71 by the lysine methyltransferase KMT7. J Biol Chem 291(31):16240–16248. https://doi.org/10.1074/jbc.M116.735415 Van Duyne R, Easley R, Wu W, Berro R, Pedati C, Klase Z, Kehn-Hall K, Flynn EK, Symer DE, Kashanchi F (2008) Lysine methylation of HIV-1 Tat regulates transcriptional activity of the viral LTR. Retrovirology 5:40. https://doi.org/10.1186/1742-4690-5-40 Mousseau G, Kessing CF, Fromentin R, Trautmann L, Chomont N, Valente ST (2015) The Tat inhibitor didehydro-cortistatin A prevents HIV-1 reactivation from latency. MBio 6(4):e00465. https://doi.org/10.1128/mBio.00465-15 Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF (2014) New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20(4):425–429. https://doi.org/10.1038/nm.3489 Rasmussen TA, Lewin SR (2016) Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents? Curr Opin HIV AIDS 11(4):394–401. https://doi.org/10.1097/COH.0000000000000279 Uchil PD, Quinlan BD, Chan WT, Luna JM, Mothes W (2008) TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog 4(2):e16. https://doi.org/10.1371/journal.ppat.0040016 Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M, Schenkova K, Ambiel I, Wabnitz G, Gramberg T, Panitz S, Flory E, Landau NR, Sertel S, Rutsch F, Lasitschka F, Kim B, Konig R, Fackler OT, Keppler OT (2012) SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med 18(11):1682–1687. https://doi.org/10.1038/nm.2964 Bres V, Kiernan RE, Linares LK, Chable-Bessia C, Plechakova O, Treand C, Emiliani S, Peloponese JM, Jeang KT, Coux O, Scheffner M, Benkirane M (2003) A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter. Nat Cell Biol 5(8):754–761. https://doi.org/10.1038/ncb1023 Moll UM, Petrenko O (2003) The MDM2-p53 interaction. Mol Cancer Res 1(14):1001–1008 Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV, Safiran YJ, Oberoi P, Kenten JH, Phillips AC, Weissman AM, Vousden KH (2005) Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7(6):547–559. https://doi.org/10.1016/j.ccr.2005.04.029 Garber ME, Wei P, KewalRamani VN, Mayall TP, Herrmann CH, Rice AP, Littman DR, Jones KA (1998) The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev 12(22):3512–3527 Faust TB, Li Y, Jang GM, Johnson JR, Yang S, Weiss A, Krogan NJ, Frankel AD (2017) PJA2 ubiquitinates the HIV-1 Tat protein with atypical chain linkages to activate viral transcription. Sci Rep 7:45394. https://doi.org/10.1038/srep45394 El Kharroubi A, Piras G, Zensen R, Martin MA (1998) Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter. Mol Cell Biol 18(5):2535–2544 D’Orso I, Jang GM, Pastuszak AW, Faust TB, Quezada E, Booth DS, Frankel AD (2012) Transition step during assembly of HIV Tat:P-TEFb transcription complexes and transfer to TAR RNA. Mol Cell Biol 32(23):4780–4793. https://doi.org/10.1128/MCB.00206-12 Garcia JA, Harrich D, Pearson L, Mitsuyasu R, Gaynor RB (1988) Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat. EMBO J 7(10):3143–3147 Sadaie MR, Mukhopadhyaya R, Benaissa ZN, Pavlakis GN, Wong-Staal F (1990) Conservative mutations in the putative metal-binding region of human immunodeficiency virus tat disrupt virus replication. AIDS Res Hum Retroviruses 6(11):1257–1263. https://doi.org/10.1089/aid.1990.6.1257 Tahirov TH, Babayeva ND, Varzavand K, Cooper JJ, Sedore SC, Price DH (2010) Crystal structure of HIV-1 Tat complexed with human P-TEFb. Nature 465(7299):747–751. https://doi.org/10.1038/nature09131 Rice AP, Carlotti F (1990) Mutational analysis of the conserved cysteine-rich region of the human immunodeficiency virus type 1 Tat protein. J Virol 64(4):1864–1868 Reza SM, Rosetti M, Mathews MB, Pe’ery T (2003) Differential activation of Tat variants in mitogen-stimulated cells: implications for HIV-1 postintegration latency. Virology 310(1):141–156 Huet T, Dazza MC, Brun-Vezinet F, Roelants GE, Wain-Hobson S (1989) A highly defective HIV-1 strain isolated from a healthy Gabonese individual presenting an atypical western blot. AIDS 3(11):707–715 Pantano S, Tyagi M, Giacca M, Carloni P (2004) Molecular dynamics simulations on HIV-1 Tat. Eur Biophys J 33(4):344–351. https://doi.org/10.1007/s00249-003-0358-z Mele AR, Marino J, Chen K, Pirrone V, Janetopoulos C, Wigdahl B, Klase Z, Nonnemacher MR (2018) Defining the molecular mechanisms of HIV-1 Tat secretion: PtdIns(4,5)P2 at the epicenter. Traffic. https://doi.org/10.1111/tra.12578 Paul RH, Joska JA, Woods C, Seedat S, Engelbrecht S, Hoare J, Heaps J, Valcour V, Ances B, Baker LM, Salminen LE, Stein DJ (2014) Impact of the HIV Tat C30C31S dicysteine substitution on neuropsychological function in patients with clade C disease. J Neurovirol 20(6):627–635. https://doi.org/10.1007/s13365-014-0293-z Berkhout B, Gatignol A, Rabson AB, Jeang KT (1990) TAR-independent activation of the HIV-1 LTR: evidence that tat requires specific regions of the promoter. Cell 62(4):757–767 Harrich D, Garcia J, Mitsuyasu R, Gaynor R (1990) TAR independent activation of the human immunodeficiency virus in phorbol ester stimulated T lymphocytes. EMBO J 9(13):4417–4423 Southgate CD, Green MR (1991) The HIV-1 Tat protein activates transcription from an upstream DNA-binding site: implications for Tat function. Genes Dev 5(12B):2496–2507 Verhoef K, Koper M, Berkhout B (1997) Determination of the minimal amount of Tat activity required for human immunodeficiency virus type 1 replication. Virology 237(2):228–236. https://doi.org/10.1006/viro.1997.8786 Das AT, Harwig A, Berkhout B (2011) The HIV-1 Tat protein has a versatile role in activating viral transcription. J Virol 85(18):9506–9516. https://doi.org/10.1128/JVI.00650-11 Dandekar DH, Ganesh KN, Mitra D (2004) HIV-1 Tat directly binds to NFkappaB enhancer sequence: role in viral and cellular gene expression. Nucleic Acids Res 32(4):1270–1278. https://doi.org/10.1093/nar/gkh289 Antell GC, Dampier W, Aiamkitsumrit B, Nonnemacher MR, Jacobson JM, Pirrone V, Zhong W, Kercher K, Passic S, Williams JW, Schwartz G, Hershberg U, Krebs FC, Wigdahl B (2016) Utilization of HIV-1 envelope V3 to identify X4- and R5-specific Tat and LTR sequence signatures. Retrovirology 13(1):32. https://doi.org/10.1186/s12977-016-0266-9 Qin JY, Zhang L, Clift KL, Hulur I, Xiang AP, Ren BZ, Lahn BT (2010) Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS One 5(5):e10611. https://doi.org/10.1371/journal.pone.0010611 Das AT, Harwig A, Vrolijk MM, Berkhout B (2007) The TAR hairpin of human immunodeficiency virus type 1 can be deleted when not required for Tat-mediated activation of transcription. J Virol 81(14):7742–7748. https://doi.org/10.1128/JVI.00392-07 Marzio G, Verhoef K, Vink M, Berkhout B (2001) In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies. Proc Natl Acad Sci USA 98(11):6342–6347. https://doi.org/10.1073/pnas.111031498 Das AT, Verhoef K, Berkhout B (2004) A conditionally replicating virus as a novel approach toward an HIV vaccine. Methods Enzymol 388:359–379. https://doi.org/10.1016/S0076-6879(04)88028-5 Mahlknecht U, Dichamp I, Varin A, Van Lint C, Herbein G (2008) NF-kappaB-dependent control of HIV-1 transcription by the second coding exon of Tat in T cells. J Leukoc Biol 83(3):718–727. https://doi.org/10.1189/jlb.0607405 Yang L, Morris GF, Lockyer JM, Lu M, Wang Z, Morris CB (1997) Distinct transcriptional pathways of TAR-dependent and TAR-independent human immunodeficiency virus type-1 transactivation by Tat. Virology 235(1):48–64. https://doi.org/10.1006/viro.1997.8672 Taylor JP, Pomerantz RJ, Raj GV, Kashanchi F, Brady JN, Amini S, Khalili K (1994) Central nervous system-derived cells express a kappa B-binding activity that enhances human immunodeficiency virus type 1 transcription in vitro and facilitates TAR-independent transactivation by Tat. J Virol 68(6):3971–3981 Gendelman HE, Lipton SA, Tardieu M, Bukrinsky MI, Nottet HS (1994) The neuropathogenesis of HIV-1 infection. J Leukoc Biol 56(3):389–398 Zhou L, Saksena NK (2013) HIV Associated Neurocognitive Disorders. Infect Dis Rep 5(Suppl 1):e8. https://doi.org/10.4081/idr.2013.s1.e8 Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24(9):1243–1250. https://doi.org/10.1097/QAD.0b013e3283354a7b Purvis SF, Jacobberger JW, Sramkoski RM, Patki AH, Lederman MM (1995) HIV type 1 Tat protein induces apoptosis and death in Jurkat cells. AIDS Res Hum Retroviruses 11(4):443–450. https://doi.org/10.1089/aid.1995.11.443 Aksenov MY, Aksenova MV, Mactutus CF, Booze RM (2009) Attenuated neurotoxicity of the transactivation-defective HIV-1 Tat protein in hippocampal cell cultures. Exp Neurol 219(2):586–590. https://doi.org/10.1016/j.expneurol.2009.07.005 McCloskey TW, Ott M, Tribble E, Khan SA, Teichberg S, Paul MO, Pahwa S, Verdin E, Chirmule N (1997) Dual role of HIV Tat in regulation of apoptosis in T cells. J Immunol 158(2):1014–1019 Kruman II, Nath A, Mattson MP (1998) HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. Exp Neurol 154(2):276–288. https://doi.org/10.1006/exnr.1998.6958 Li CJ, Friedman DJ, Wang C, Metelev V, Pardee AB (1995) Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 268(5209):429–431 Pantaleo G, Fauci AS (1995) Apoptosis in HIV infection. Nat Med 1(2):118–120 Sood V, Ranjan R, Banerjea AC (2008) Functional analysis of HIV-1 subtypes B and C HIV-1 Tat exons and RGD/QGD motifs with respect to Tat-mediated transactivation and apoptosis. AIDS 22(13):1683–1685. https://doi.org/10.1097/QAD.0b013e3282f56114 Chen D, Wang M, Zhou S, Zhou Q (2002) HIV-1 Tat targets microtubules to induce apoptosis, a process promoted by the pro-apoptotic Bcl-2 relative Bim. EMBO J 21(24):6801–6810 Peter ME, Ehret A, Berndt C, Krammer PH (1997) AIDS and the death receptors. Br Med Bull 53(3):604–616 Herbeuval JP, Grivel JC, Boasso A, Hardy AW, Chougnet C, Dolan MJ, Yagita H, Lifson JD, Shearer GM (2005) CD4 + T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood 106(10):3524–3531. https://doi.org/10.1182/blood-2005-03-1243 Garden GA, Budd SL, Tsai E, Hanson L, Kaul M, D’Emilia DM, Friedlander RM, Yuan J, Masliah E, Lipton SA (2002) Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci 22(10):4015–4024. (20026351) Taylor RC, Cullen SP, Martin SJ (2008) Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9(3):231–241. https://doi.org/10.1038/nrm2312 Campbell GR, Watkins JD, Esquieu D, Pasquier E, Loret EP, Spector SA (2005) The C terminus of HIV-1 Tat modulates the extent of CD178-mediated apoptosis of T cells. J Biol Chem 280(46):38376–38382. https://doi.org/10.1074/jbc.M506630200 Bartz SR, Emerman M (1999) Human immunodeficiency virus type 1 Tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/caspase-8. J Virol 73(3):1956–1963 Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35(4):495–516. https://doi.org/10.1080/01926230701320337 Kamori D, Ueno T (2017) HIV-1 Tat and viral latency: what we can learn from naturally occurring sequence variations. Front Microbiol 8:80. https://doi.org/10.3389/fmicb.2017.00080 Campbell GR, Pasquier E, Watkins J, Bourgarel-Rey V, Peyrot V, Esquieu D, Barbier P, de Mareuil J, Braguer D, Kaleebu P, Yirrell DL, Loret EP (2004) The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis. J Biol Chem 279(46):48197–48204. https://doi.org/10.1074/jbc.M406195200 de Mareuil J, Carre M, Barbier P, Campbell GR, Lancelot S, Opi S, Esquieu D, Watkins JD, Prevot C, Braguer D, Peyrot V, Loret EP (2005) HIV-1 Tat protein enhances microtubule polymerization. Retrovirology 2:5. https://doi.org/10.1186/1742-4690-2-5 Battaglia PA, Zito S, Macchini A, Gigliani F (2001) A Drosophila model of HIV-Tat-related pathogenicity. J Cell Sci 114(Pt 15):2787–2794 Alizon M, Wain-Hobson S, Montagnier L, Sonigo P (1986) Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients. Cell 46(1):63–74 Egele C, Barbier P, Didier P, Piemont E, Allegro D, Chaloin O, Muller S, Peyrot V, Mely Y (2008) Modulation of microtubule assembly by the HIV-1 Tat protein is strongly dependent on zinc binding to Tat. Retrovirology 5:62. https://doi.org/10.1186/1742-4690-5-62 Strack PR, Frey MW, Rizzo CJ, Cordova B, George HJ, Meade R, Ho SP, Corman J, Tritch R, Korant BD (1996) Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2. Proc Natl Acad Sci USA 93(18):9571–9576 Jacotot E, Ferri KF, El Hamel C, Brenner C, Druillennec S, Hoebeke J, Rustin P, Metivier D, Lenoir C, Geuskens M, Vieira HL, Loeffler M, Belzacq AS, Briand JP, Zamzami N, Edelman L, Xie ZH, Reed JC, Roques BP, Kroemer G (2001) Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2. J Exp Med 193(4):509–519 Zauli G, Gibellini D (1996) The human immunodeficiency virus type-1 (HIV-1) Tat protein and Bcl-2 gene expression. Leuk Lymphoma 23(5–6):551–560. https://doi.org/10.3109/10428199609054864 Zauli G, Gibellini D, Caputo A, Bassini A, Negrini M, Monne M, Mazzoni M, Capitani S (1995) The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells. Blood 86(10):3823–3834 Sastry KJ, Marin MC, Nehete PN, McConnell K, el-Naggar AK, McDonnell TJ (1996) Expression of human immunodeficiency virus type I tat results in down-regulation of bcl-2 and induction of apoptosis in hematopoietic cells. Oncogene 13(3):487–493 Zauli G, Gibellini D, Milani D, Mazzoni M, Borgatti P, La Placa M, Capitani S (1993) Human immunodeficiency virus type 1 Tat protein protects lymphoid, epithelial, and neuronal cell lines from death by apoptosis. Cancer Res 53(19):4481–4485 Gibellini D, Caputo A, Celeghini C, Bassini A, La Placa M, Capitani S, Zauli G (1995) Tat-expressing Jurkat cells show an increased resistance to different apoptotic stimuli, including acute human immunodeficiency virus-type 1 (HIV-1) infection. Br J Haematol 89(1):24–33 Zhang M, Li X, Pang X, Ding L, Wood O, Clouse KA, Hewlett I, Dayton AI (2002) Bcl-2 upregulation by HIV-1 Tat during infection of primary human macrophages in culture. J Biomed Sci 9(2):133–139. https://doi.org/10.1159/000048209 Lafrenie RM, Wahl LM, Epstein JS, Hewlett IK, Yamada KM, Dhawan S (1996) HIV-1-Tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells. A mechanism of HIV pathogenesis. J Immunol 156(4):1638–1645 Toborek M, Lee YW, Pu H, Malecki A, Flora G, Garrido R, Hennig B, Bauer HC, Nath A (2003) HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J Neurochem 84(1):169–179 Raidel SM, Haase C, Jansen NR, Russ RB, Sutliff RL, Velsor LW, Day BJ, Hoit BD, Samarel AM, Lewis W (2002) Targeted myocardial transgenic expression of HIV Tat causes cardiomyopathy and mitochondrial damage. Am J Physiol Heart Circ Physiol 282(5):H1672–H1678. https://doi.org/10.1152/ajpheart.00955.2001 Paladugu R, Fu W, Conklin BS, Lin PH, Lumsden AB, Yao Q, Chen C (2003) Hiv Tat protein causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg 38(3):549–555. (discussion 555–546) Rusnati M, Presta M (2002) HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis 5(3):141–151 Koch S, Claesson-Welsh L (2012) Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med 2(7):a006502. https://doi.org/10.1101/cshperspect.a006502 Albini A, Soldi R, Giunciuglio D, Giraudo E, Benelli R, Primo L, Noonan D, Salio M, Camussi G, Rockl W, Bussolino F (1996) The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med 2(12):1371–1375 Albini A, Benelli R, Presta M, Rusnati M, Ziche M, Rubartelli A, Paglialunga G, Bussolino F, Noonan D (1996) HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene 12(2):289–297 Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669–676. https://doi.org/10.1038/nm0603-669 Dhawan S, Puri RK, Kumar A, Duplan H, Masson JM, Aggarwal BB (1997) Human immunodeficiency virus-1-tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells. Blood 90(4):1535–1544 Mitola S, Soldi R, Zanon I, Barra L, Gutierrez MI, Berkhout B, Giacca M, Bussolino F (2000) Identification of specific molecular structures of human immunodeficiency virus type 1 Tat relevant for its biological effects on vascular endothelial cells. J Virol 74(1):344–353 Toborek M, Lee YW, Flora G, Pu H, Andras IE, Wylegala E, Hennig B, Nath A (2005) Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol 25(1):181–199 Vene R, Benelli R, Noonan DM, Albini A (2000) HIV-Tat dependent chemotaxis and invasion, key aspects of tat mediated pathogenesis. Clin Exp Metastasis 18(7):533–538 Benelli R, Mortarini R, Anichini A, Giunciuglio D, Noonan DM, Montalti S, Tacchetti C, Albini A (1998) Monocyte-derived dendritic cells and monocytes migrate to HIV-Tat RGD and basic peptides. AIDS 12(3):261–268 Albini A, Benelli R, Giunciuglio D, Cai T, Mariani G, Ferrini S, Noonan DM (1998) Identification of a novel domain of HIV tat involved in monocyte chemotaxis. J Biol Chem 273(26):15895–15900 Premack BA, Schall TJ (1996) Chemokine receptors: gateways to inflammation and infection. Nat Med 2(11):1174–1178 Conant K, Garzino-Demo A, Nath A, McArthur JC, Halliday W, Power C, Gallo RC, Major EO (1998) Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci USA 95(6):3117–3121 Bonwetsch R, Croul S, Richardson MW, Lorenzana C, Del Valle L, Sverstiuk AE, Amini S, Morgello S, Khalili K, Rappaport J (1999) Role of HIV-1 Tat and CC chemokine MIP-1alpha in the pathogenesis of HIV associated central nervous system disorders. J Neurovirol 5(6):685–694 Weiss JM, Nath A, Major EO, Berman JW (1999) HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. J Immunol 163(5):2953–2959 Geiss GK, Bumgarner RE, An MC, Agy MB, van ‘t Wout AB, Hammersmark E, Carter VS, Upchurch D, Mullins JI, Katze MG (2000) Large-scale monitoring of host cell gene expression during HIV-1 infection using cDNA microarrays. Virology 266(1):8–16. https://doi.org/10.1006/viro.1999.0044 Fan J, Bass HZ, Fahey JL (1993) Elevated IFN-gamma and decreased IL-2 gene expression are associated with HIV infection. J Immunol 151(9):5031–5040 Lafrenie RM, Wahl LM, Epstein JS, Yamada KM, Dhawan S (1997) Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. J Immunol 159(8):4077–4083 Nath A, Conant K, Chen P, Scott C, Major EO (1999) Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J Biol Chem 274(24):17098–17102 Kiernan R, Bres V, Ng RW, Coudart MP, El Messaoudi S, Sardet C, Jin DY, Emiliani S, Benkirane M (2003) Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 278(4):2758–2766. https://doi.org/10.1074/jbc.M209572200 Lenardo MJ, Baltimore D (1989) NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 58(2):227–229 Kwon HS, Brent MM, Getachew R, Jayakumar P, Chen LF, Schnolzer M, McBurney MW, Marmorstein R, Greene WC, Ott M (2008) Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe 3(3):158–167. https://doi.org/10.1016/j.chom.2008.02.002 Bachmann MF, Oxenius A (2007) Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep 8(12):1142–1148. https://doi.org/10.1038/sj.embor.7401099 Ott M, Emiliani S, Van Lint C, Herbein G, Lovett J, Chirmule N, McCloskey T, Pahwa S, Verdin E (1997) Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 275(5305):1481–1485 Carvallo L, Lopez L, Fajardo JE, Jaureguiberry-Bravo M, Fiser A, Berman JW (2017) HIV-Tat regulates macrophage gene expression in the context of neuroAIDS. PLoS One 12(6):e0179882. https://doi.org/10.1371/journal.pone.0179882 Bouwman RD, Palser A, Parry CM, Coulter E, Rasaiyaah J, Kellam P, Jenner RG (2014) Human immunodeficiency virus Tat associates with a specific set of cellular RNAs. Retrovirology 11:53. https://doi.org/10.1186/1742-4690-11-53 Sharma V, Knobloch TJ, Benjamin D (1995) Differential expression of cytokine genes in HIV-1 tat transfected T and B cell lines. Biochem Biophys Res Commun 208(2):704–713. https://doi.org/10.1006/bbrc.1995.1395 Dabrowska A, Kim N, Aldovini A (2008) Tat-induced FOXO3a is a key mediator of apoptosis in HIV-1-infected human CD4 + T lymphocytes. J Immunol 181(12):8460–8477 Izmailova E, Bertley FM, Huang Q, Makori N, Miller CJ, Young RA, Aldovini A (2003) HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages. Nat Med 9(2):191–197. https://doi.org/10.1038/nm822 Ranjbar S, Rajsbaum R, Goldfeld AE (2006) Transactivator of transcription from HIV type 1 subtype E selectively inhibits TNF gene expression via interference with chromatin remodeling of the TNF locus. J Immunol 176(7):4182–4190 Karin M, Lin A (2002) NF-kappaB at the crossroads of life and death. Nat Immunol 3(3):221–227. https://doi.org/10.1038/ni0302-221 Israel N, Hazan U, Alcami J, Munier A, Arenzana-Seisdedos F, Bachelerie F, Israel A, Virelizier JL (1989) Tumor necrosis factor stimulates transcription of HIV-1 in human T lymphocytes, independently and synergistically with mitogens. J Immunol 143(12):3956–3960 Hiscott J, Kwon H, Genin P (2001) Hostile takeovers: viral appropriation of the NF-kappaB pathway. J Clin Invest 107(2):143–151. https://doi.org/10.1172/JCI11918 Nath A, Psooy K, Martin C, Knudsen B, Magnuson DS, Haughey N, Geiger JD (1996) Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J Virol 70(3):1475–1480 Li W, Huang Y, Reid R, Steiner J, Malpica-Llanos T, Darden TA, Shankar SK, Mahadevan A, Satishchandra P, Nath A (2008) NMDA receptor activation by HIV-Tat protein is clade dependent. J Neurosci 28(47):12190–12198. https://doi.org/10.1523/JNEUROSCI.3019-08.2008 Dawson VL, Dawson TM, Bartley DA, Uhl GR, Snyder SH (1993) Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci 13(6):2651–2661 Sengpiel B, Preis E, Krieglstein J, Prehn JH (1998) NMDA-induced superoxide production and neurotoxicity in cultured rat hippocampal neurons: role of mitochondria. Eur J Neurosci 10(5):1903–1910 Bertrand SJ, Aksenova MV, Mactutus CF, Booze RM (2013) HIV-1 Tat protein variants: critical role for the cysteine region in synaptodendritic injury. Exp Neurol 248:228–235. https://doi.org/10.1016/j.expneurol.2013.06.020 Zhang W, Benson DL (2001) Stages of synapse development defined by dependence on F-actin. J Neurosci 21(14):5169–5181 Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE (1992) beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12(2):376–389 Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ, Cotman CW (1993) Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA 90(17):7951–7955 Holscher C (2005) Development of beta-amyloid-induced neurodegeneration in Alzheimer’s disease and novel neuroprotective strategies. Rev Neurosci 16(3):181–212 Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL (2005) Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 19(4):407–411 Achim CL, Adame A, Dumaop W, Everall IP, Masliah E, Neurobehavioral Research C (2009) Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol 4(2):190–199. https://doi.org/10.1007/s11481-009-9152-8 Chen X, Hui L, Geiger NH, Haughey NJ, Geiger JD (2013) Endolysosome involvement in HIV-1 transactivator protein-induced neuronal amyloid beta production. Neurobiol Aging 34(10):2370–2378. https://doi.org/10.1016/j.neurobiolaging.2013.04.015 Nixon RA, Cataldo AM (1995) The endosomal-lysosomal system of neurons: new roles. Trends Neurosci 18(11):489–496 Bahr BA, Bendiske J (2002) The neuropathogenic contributions of lysosomal dysfunction. J Neurochem 83(3):481–489 Annaert W, De Strooper B (2002) A cell biological perspective on Alzheimer’s disease. Annu Rev Cell Dev Biol 18:25–51. https://doi.org/10.1146/annurev.cellbio.18.020402.142302 Kim J, Yoon JH, Kim YS (2013) HIV-1 Tat interacts with and regulates the localization and processing of amyloid precursor protein. PLoS One 8(11):e77972. https://doi.org/10.1371/journal.pone.0077972 Hategan A, Bianchet MA, Steiner J, Karnaukhova E, Masliah E, Fields A, Lee MH, Dickens AM, Haughey N, Dimitriadis EK, Nath A (2017) HIV Tat protein and amyloid-beta peptide form multifibrillar structures that cause neurotoxicity. Nat Struct Mol Biol 24(4):379–386. https://doi.org/10.1038/nsmb.3379 Aksenov MY, Aksenova MV, Mactutus CF, Booze RM (2010) HIV-1 protein-mediated amyloidogenesis in rat hippocampal cell cultures. Neurosci Lett 475(3):174–178. https://doi.org/10.1016/j.neulet.2010.03.073 Johri MK, Sharma N, Singh SK (2015) HIV Tat protein: Is Tat-C much trickier than Tat-B? J Med Virol 87(8):1334–1343. https://doi.org/10.1002/jmv.24182 Kurosu T, Mukai T, Komoto S, Ibrahim MS, Li YG, Kobayashi T, Tsuji S, Ikuta K (2002) Human immunodeficiency virus type 1 subtype C exhibits higher transactivation activity of Tat than subtypes B and E. Microbiol Immunol 46(11):787–799 Gandhi N, Saiyed Z, Thangavel S, Rodriguez J, Rao KV, Nair MP (2009) Differential effects of HIV type 1 clade B and clade C Tat protein on expression of proinflammatory and antiinflammatory cytokines by primary monocytes. AIDS Res Hum Retroviruses 25(7):691–699. https://doi.org/10.1089/aid.2008.0299 Bayes-Genis A, Barallat J, Richards AM (2016) A test in context: neprilysin: function, inhibition, and biomarker. J Am Coll Cardiol 68(6):639–653. https://doi.org/10.1016/j.jacc.2016.04.060 Rempel HC, Pulliam L (2005) HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS 19(2):127–135 Daily A, Nath A, Hersh LB (2006) Tat peptides inhibit neprilysin. J Neurovirol 12(3):153–160. https://doi.org/10.1080/13550280600760677 Hamley IW (2012) The amyloid beta peptide: a chemist’s perspective. Role in Alzheimer’s and fibrillization. Chem Rev 112(10):5147–5192. https://doi.org/10.1021/cr3000994 Butterfield DA (2002) Amyloid beta-peptide (1–42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer’s disease brain. A review. Free Radic Res 36(12):1307–1313 Tanzi RE, Bertram L (2005) Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell 120(4):545–555. https://doi.org/10.1016/j.cell.2005.02.008 Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, O’Sullivan KM, Desouza I, Feeney ME, Eldridge RL, Maier EL, Kaufmann DE, Lahaie MP, Reyor L, Tanzi G, Johnston MN, Brander C, Draenert R, Rockstroh JK, Jessen H, Rosenberg ES, Mallal SA, Walker BD (2005) Selective escape from CD8 + T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 79(21):13239–13249. https://doi.org/10.1128/JVI.79.21.13239-13249.2005 Allen TM, O’Connor DH, Jing P, Dzuris JL, Mothe BR, Vogel TU, Dunphy E, Liebl ME, Emerson C, Wilson N, Kunstman KJ, Wang X, Allison DB, Hughes AL, Desrosiers RC, Altman JD, Wolinsky SM, Sette A, Watkins DI (2000) Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407(6802):386–390. https://doi.org/10.1038/35030124 Xiao H, Neuveut C, Tiffany HL, Benkirane M, Rich EA, Murphy PM, Jeang KT (2000) Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci USA 97(21):11466–11471. https://doi.org/10.1073/pnas.97.21.11466 Desfosses Y, Solis M, Sun Q, Grandvaux N, Van Lint C, Burny A, Gatignol A, Wainberg MA, Lin R, Hiscott J (2005) Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins. J Virol 79(14):9180–9191. https://doi.org/10.1128/JVI.79.14.9180-9191.2005 Landry JJ, Pyl PT, Rausch T, Zichner T, Tekkedil MM, Stutz AM, Jauch A, Aiyar RS, Pau G, Delhomme N, Gagneur J, Korbel JO, Huber W, Steinmetz LM (2013) The genomic and transcriptomic landscape of a HeLa cell line. G3 (Bethesda) 3(8):1213–1224. https://doi.org/10.1534/g3.113.005777 Frattini A, Fabbri M, Valli R, De Paoli E, Montalbano G, Gribaldo L, Pasquali F, Maserati E (2015) High variability of genomic instability and gene expression profiling in different HeLa clones. Sci Rep 5:15377. https://doi.org/10.1038/srep15377 Mousseau G, Clementz MA, Bakeman WN, Nagarsheth N, Cameron M, Shi J, Baran P, Fromentin R, Chomont N, Valente ST (2012) An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription. Cell Host Microbe 12(1):97–108. https://doi.org/10.1016/j.chom.2012.05.016 Ferrucci A, Nonnemacher MR, Wigdahl B (2011) Human immunodeficiency virus viral protein R as an extracellular protein in neuropathogenesis. Adv Virus Res 81:165–199. https://doi.org/10.1016/B978-0-12-385885-6.00010-9 James T, Nonnemacher MR, Wigdahl B, Krebs FC (2016) Defining the roles for Vpr in HIV-1-associated neuropathogenesis. J Neurovirol 22(4):403–415. https://doi.org/10.1007/s13365-016-0436-5 Dampier W, Antell GC, Aiamkitsumrit B, Nonnemacher MR, Jacobson JM, Pirrone V, Zhong W, Kercher K, Passic S, Williams JW, James T, Devlin KN, Giovannetti T, Libon DJ, Szep Z, Ehrlich GD, Wigdahl B, Krebs FC (2017) Specific amino acids in HIV-1 Vpr are significantly associated with differences in patient neurocognitive status. J Neurovirol 23(1):113–124. https://doi.org/10.1007/s13365-016-0462-3 Hogan TH, Nonnemacher MR, Krebs FC, Henderson A, Wigdahl B (2003) HIV-1 Vpr binding to HIV-1 LTR C/EBP cis-acting elements and adjacent regions is sequence-specific. Biomed Pharmacother 57(1):41–48 Yiannopoulou KG, Papageorgiou SG (2013) Current and future treatments for Alzheimer’s disease. Ther Adv Neurol Disord 6(1):19–33. https://doi.org/10.1177/1756285612461679 Rygiel K (2016) Novel strategies for Alzheimer’s disease treatment: An overview of anti-amyloid beta monoclonal antibodies. Indian J Pharmacol 48(6):629–636. https://doi.org/10.4103/0253-7613.194867